To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >
X
Search

U266B1 [U266] (ATCC® TIB-196™)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Tissue: peripheral blood  /  Disease: myeloma; plasmacytoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue
peripheral blood
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease myeloma; plasmacytoma
Age 53 years adult
Gender male
Applications
This cell line is a suitable transfection host.
Images Cell Micrograph of ATCC TIB-196, U266B1
Clinical Data
male
Genes Expressed
immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
Cellular Products
immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
Comments
U266 cells have been reported to produce human IL-6.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Subculturing
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 105 cells/mL and maintain between 1 x 105 and 1 x 106 cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.
Medium Renewal: Every 2 to 3 days
Cryopreservation
culture medium 95%; DMSO, 5%
STR Profile
Amelogenin: X,Y
CSF1PO: 12,13
D13S317: 12
D16S539: 10
D5S818: 11,12
D7S820: 11,12
TH01: 5,7
TPOX: 8
vWA: 17
Isotype IgE; lambda light chain
Name of Depositor NK Nilsson
Deposited As Homo sapiens
References

Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745

Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060

Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
Cell Micrograph
References

Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745

Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060

Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128